Background {#Sec1}
==========

Early detection of cancer has improved the survival of patients with many types of cancer and is critical for future improvements in effectively treating the disease \[[@CR1]\]. The detection of serum tumor markers is an effective and non-invasive diagnostic or prognostic tool for pancreatic cancer. The two major reasons that most tumor markers are not used for tumor screening are their low sensitivity and specificity, resulting in low detection rates and unacceptable false-positive diagnoses \[[@CR2]\]. The examination of combined tumor markers might improve the sensitivity or specificity \[[@CR3]\].

The purpose of this study was to evaluate the diagnostic value of multi-tumor marker protein biochip detection for pancreatic cancer. This protein biochip system quantitatively measured 12 common tumor markers, including cancer antigen (CA)125, CA15-3, CA19-9, CA242, carcinoembryonic antigen (CEA), R-fetoprotein (AFP), prostate specific antigen (PSA), free-prostate specific antigen (f-PSA), human growth hormone (HGH), β-human chorionic gonadotropin (β-HCG), neuron-specific enolase (NSE) and ferritin (FER), in the serum and was tested in clinically confirmed cancer patients and apparently healthy individuals. The value of this biochip in cancer screening of apparently healthy populations and in cancer patients is discussed.

Methods {#Sec2}
=======

Patients and serum samples {#Sec3}
--------------------------

From June 2012 to October 2013, 235 patients (150 men and 85 women, median age 61 years, range 20 to 78 years) with pancreatic cancer were included in the study group. One hundred and fifteen patients were treated with pancreaticoduodenectomy or distal pancreatectomy and 120 patients underwent a palliative operation. According to the *TNM Classification, fifth edition* \[[@CR4]\], there were 22 stage I patients, 140 stage II patients and 73 stage III patients. The location of tumor was divided into head (48 cases), body/tail (146 cases) and the whole pancreas (59 cases). The tumor size was divided into equal to (12 cases) and smaller than 5 cm (154 cases), or larger than 5 cm (69 cases) in diameter. All diagnoses were confirmed by histology of postoperative or cytology of intraoperative biopsy examination. In addition, there were 230 benign pancreatic diseases (100 chronic pancreatitis and 130 benign adenomas, including 61 men and 39 women, age ranging from 20 to 82 years), and 240 blood donors and other volunteers known to be in good health.

Sample preparation {#Sec4}
------------------

Horseradish peroxidase (HRP) and chemiluminescence substrates (SuperSignal Femto maximum sensitivity) were purchased from Pierce (Rockford, IL, USA). Antigens and antibodies were produced in our laboratory. Antibody conjugation was done according to Nakane and Kawaio's article \[[@CR5]\].

Sample measurement {#Sec5}
------------------

One point five microliters of each of the 12 capture antibodies, with an average concentration of 1 mg/mL, were arrayed in duplicates on a 1 × 1 cm nitrocellulose membrane. The array consisted of a 5 × 5 matrix with 12 pairs of antibody spots and 1 blank spot as control. After spotting, the membrane was mounted with a plastic mold and blocked with 10% BSA. Each protein chip was incubated with 100 μL of serum, rinsed and washed with TBST (0.1 mol Tris-HCl, 8.5 g NaCl, 1 mL Tween 20, pH 7.6). The chip was then incubated with 100 μL of HRP-labeled antibodies for 30 minutes at 37°C and again rinsed and washed with TBST. Chemiluminescence substrates were added for 1 minute. Light signals were captured with the self-built chip reader based on a CCD camera and controlled with a computer system using self-developed software. The workflow of the chip detection system is shown in Figure [1](#Fig1){ref-type="fig"}.Figure 1**The workflow of the chip detection system.**

Statistical analysis {#Sec6}
--------------------

Due to non-normal distribution of the raw data, a logarithmic transformation was needed. Data collected were subjected to appropriate transformation (square root) before analysis of variance was performed and means were separated by SAS-SNK (*P* \<0.05) test (SAS Institute, Cary, NC, USA; 1989).

Results {#Sec7}
=======

Positive detection rates of tumor markers were: CA19-9 (49.3%), CA125 (45.1%), FER (44.2%), CA242 (42.5%), CEA (38.6%), CA15-3 (36.7%), β-HCG (29.6%), AFP (24.5%), NSE (18.2%), PSA (19.5%), f-PSA (9.4%) and HGH (8.7%) respectively (Table [1](#Tab1){ref-type="table"}).Table 1**Twelve (C-12) protein biochip test results of healthy, benign pancreatic and pancreatic cancer subjects**HealthyBenign pancreaticPancreatic cancer***P***-value(n =240)(n =230)(n =235)(SNK method)CA19-9 (U/ml)4.5 ± 2. 816.4 ± 19.2203.8 ± 296.50. 0008CA125 (U/ml)2.9 ± 2. 618.9 ± 28.7174.6 ± 266.20. 0016FER (ng/ml)118.9 ± 62.6320.9 ± 285373.8 ± 385.50. 5579CA242 (U/ml)2.3 ± 0.89.3 ± 14.7130.5 ± 150.50. 0035CEA (ng/ml)1.1 ± 0.51.87 ± 2.313.5 ± 27.10. 0392CA15-3 (U/ml)5.1 ± 4.213.4 ± 6.879.4 ± 82.30. 0584β-HCG (mIU/ml)0.1 ± 0.10.5 ± 0.48.96 ± 12.80. 0694AFP (ng/ml)3.3 ± 2.41.6 ± 1.814.5 ± 36.80. 0568NSE (ng/ml)1.3 ± 0.82.1 ± 2.37.9 ± 12.80. 0179PSA (ng/ml)0.3 ± 0.20.6 ± 0.51.5 ± 2.380. 0575f-PSA (ng/ml)0.1 ± 0.10.2 ± 0.20.6 ± 0.60. 1046HGH (ng/ml)0.1 ± 0.20.8 ± 0.74.5 ± 4.80. 0564

There was significant difference in CA19-9, NSE, CEA, CA242, CA125 by multi-tumor marker protein biochip detection among patients with cancer, benign disease and apparently healthy people (*P* \<0.05). We took the normal value of tumor marker serum level as cut-off value to determine the negative or positive likelihood of pancreatic cancer. The positive rate of 5 tumor markers was 94.9%, which was much higher than that of any single marker (Table [2](#Tab2){ref-type="table"}). Figure [2](#Fig2){ref-type="fig"} shows the receiver operating characteristic (ROC) curves of the 5 markers. The diagnostic performance of markers was ranked according to the area under the curves.Table 2**Positive rate of pancreatic cancer versus benign pancreatic disease**Pancreatic cancerBenign pancreatic disease(n =235)(n =230)CA19-9 (U/ml)49.3%14.2%CA125 (U/ml)47.3%13.6%FER (ng/ml)43.2%49.2%CA242 (U/ml)42.7%23.6%CEA (ng/ml)36.4%14.8%CA15-3 (U/ml)28.7%0β-HCG (mIU/ml)25.5%0AFP (ng/ml)20.4%0NSE (ng/ml)18.9%0PSA (ng/ml)13.5%0f-PSA (ng/ml)14.1%0Source of the curve: ------ The combined five markers, - - - CEA, · · · CA125, · · · CA15-3, ------ Reference line.Figure 2**ROC curve.**

It was noticed that the CA19-9 levels were significantly higher in patients with cancer of the pancreatic body and tail than of the pancreatic head (*P* =0.047). There was no correlation of serum CEA and CA242 with tumor location (*P* \>0.05). The serum levels of CEA, CA19-9, and CA242 were obviously higher in stage III patients than in stages I and II (*P* \<0.05). However, the serum levels of CEA, CA19-9 and CA242 in patients with pancreatic cancer were not affected by the tumor size (*P* \>0.05) (Table [3](#Tab3){ref-type="table"}).Table 3**The relationship between the serum markers and the location, size, and TNM stage of pancreatic cancer**GroupNumberCEACA19-9CA242value (ng/ml)***P***-valuevalue (ng/ml)***P***-valuevalue (ng/ml)***P***-valueTumor location\
head4820.6 ± 42.6756.6 ± 1,228.258.3 ± 55.3Body/tail14628.0 ± 33.12,902.5 ± 3,308.376.1 ± 72.1Whole5974.9 ± 232.1*P* \>0.51,517.3 ± 2,928.6*P* \<0.572.6 ± 60.3*P* \>0.5Tumor size≤ 5 cm16623.7 ± 39.11,113.4 ± 2,660.445.2 ± 48.1\> 5 cm6923.9 ± 36.3*P* \>0.51,258.9 ± 5,002.3*P* \>0.559.1 ± 60.3*P* \>0.5TNM stageI2214.1 ± 16.61,126.6 ± 1,425.957.6 ± 54.4II14012.7 ± 28.3845.0 ± 2,000.753.9 ± 52.1III7390.3 ± 212.8*P* \<0.52,976.6 ± 3,513.2*P* \<0.597.6 ± 67.1*P* \<0.5

Discussion {#Sec8}
==========

Due to their limited specificity, the measurement of a single tumor marker is usually not sufficient to diagnose cancer. Impressive integration efforts are demonstrated by the ability to perform on-chip trypsin digestion, separation and injection into a mass spectrometer with a single device \[[@CR6]\]. Elevated levels of the proteins CEA, AFP, hCG-β, FER, CA15-3, CA19-9, and CA125 can be associated with lung, pancreatic, breast, colorectal, and other types of cancer \[[@CR7]--[@CR10]\]. Several studies have shown that the measurement of panels of tumor markers can improve their diagnostic value \[[@CR5]--[@CR8]\]. In previous reports, the levels of serum CEA, CA19-9 and CA242 in patients with pancreatic cancer were higher than those of other malignant diseases and benign pancreatic diseases \[[@CR7], [@CR11]\]. Here, we found that the combination of CEA and CA242 could increase the specificity to 94.9% in the diagnosis of pancreatic cancer. This is important in helping to differentiate pancreatic cancer from other malignancies and benign pancreatic diseases.

Conclusion {#Sec9}
==========

The biosensor system described here is suitable for the measurement of a wide range of biomarkers. We compared the serum levels of CA19-9, CA125, FER, CA242, CEA, CA15-3, β-HCG, AFP, NSE, PSA, f-PSA and HGH associated with pancreatic cancer, and found that simultaneous analysis of them was important for the diagnosis of pancreatic cancer. The detection of CA19-9, NSE, CEA, CA242 and CA125 in the multi-tumor markers protein biochip system is helpful in the diagnosis of pancreatic cancer.
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